Evidence map›Paper›PMID 41074120›Full record

ArticleJournal of nanobiotechnology2025

Targeting JAK2 with a multifunctional nanoinhibitor for long-lasting anti-inflammatory effects and bone repair.

Yang Liu, Duan Wang, Wenqian Zheng, Yuxuan Wang, Peiyu Wang, Yuping Zhao, Xiaofan Liu, Yaru Shi, Yi Wang, Na Zhou and 4 more

Abstract read
In one paragraph

Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Yang Liu *Department of Periodontology, Hospital of Stomatology, Jilin University, Changchun, 130021, China.
Duan Wang *Department of Periodontology, Hospital of Stomatology, Jilin University, Changchun, 130021, China.
Wenqian ZhengJilin Provincial Key Laboratory of Tooth Development and Bone Remodeling, Hospital of Stomatology, Jilin University, Changchun, 130021, China.
Yuxuan WangDepartment of Periodontology, Hospital of Stomatology, Jilin University, Changchun, 130021, China.
Peiyu WangDepartment of Periodontology, Hospital of Stomatology, Jilin University, Changchun, 130021, China.
Yuping ZhaoDepartment of Periodontology, Hospital of Stomatology, Jilin University, Changchun, 130021, China.
Xiaofan LiuJilin Provincial Key Laboratory of Tooth Development and Bone Remodeling, Hospital of Stomatology, Jilin University, Changchun, 130021, China.
Yaru ShiDepartment of Periodontology, Hospital of Stomatology, Jilin University, Changchun, 130021, China.
Yi WangGraduate Program in Applied Physics, Northwestern University, Evanston, IL, 60208, USA.
Na ZhouState Key Laboratory of Quality Research in Chinese Medicines and Laboratory of Drug Discovery from Natural Resources and Industrialization, School of Pharmacy, Macau University of Science and Technology, Macau, 999078, China.
Fermín E GonzálezLaboratory of Experimental Immunology & Cancer, Faculty of Dentistry, University of Chile, Santiago, 8380492, Chile.
Hongchen SunJilin Provincial Key Laboratory of Tooth Development and Bone Remodeling, Hospital of Stomatology, Jilin University, Changchun, 130021, China.
Ding ZhouJilin Provincial Key Laboratory of Tooth Development and Bone Remodeling, Hospital of Stomatology, Jilin University, Changchun, 130021, China. zhouding@jlu.edu.cn.
Xiaowei XuDepartment of Periodontology, Hospital of Stomatology, Jilin University, Changchun, 130021, China. xiaoweixu@jlu.edu.cn.

Funding

National Key Research and Development Program for Young Scientists 2022YFA1105800National Natural Science Foundation of China 82470957
6 · The paper itself

Abstract

Dysregulation of the JAK2/STAT3 pathway disrupts immune balance and tissue homeostasis, leading to persistent inflammation and subsequent bone loss. Yet, commonly used JAK2 inhibitors with hydrophobicity primarily suppress inflammation but often fail to provide sustained pharmacological effects and address ongoing inflammation-induced bone destruction. Here, using computer-aided drug design, we developed hydrophilic calcium-doped carbon dots (Ca-CDs) as a multifunctional nanoinhibitor targeting JAK2. The Ca-CDs can block the excessive activation of the JAK2/STAT3 pathway by binding to JAK2, thereby reducing the secretion of pro-inflammatory cytokines and exerting anti-inflammatory effects. Furthermore, the Ca-CDs promote bone regeneration under inflammatory conditions and serve as crosslinking junctions that facilitate the formation of a Ca-CDs-based alginate hydrogel, thereby enabling prolonged drug retention and controlled release. Their application in the representative inflammatory microenvironment of periodontitis successfully validated the efficacy of the Ca-CDs-based therapeutic strategy. Overall, targeting JAK2 with Ca-CDs nanoinhibitor offers a promising treatment option for JAK2-associated inflammatory diseases.

Indexed as

Anti-Inflammatory AgentsBone RegenerationJanus Kinase 2AnimalsCalciumHumansInflammationMicePeriodontitisRAW 264.7 CellsSignal TransductionSTAT3 Transcription FactorAnti-Inflammatory AgentsCalciumJanus Kinase 2STAT3 Transcription FactorAnti-inflammationBone repairCarbon dotsJAK2 nanoinhibitorSustained release

Identifiers

PMID41074120
PMCPMC12514816

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.